These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 16900551)

  • 41. A treatment allocation procedure for sequential clinical trials.
    Begg CB; Iglewicz B
    Biometrics; 1980 Mar; 36(1):81-90. PubMed ID: 7370375
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect.
    Jiang W; Freidlin B; Simon R
    J Natl Cancer Inst; 2007 Jul; 99(13):1036-43. PubMed ID: 17596577
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Repeated confidence intervals for adaptive group sequential trials.
    Mehta CR; Bauer P; Posch M; Brannath W
    Stat Med; 2007 Dec; 26(30):5422-33. PubMed ID: 17918195
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Analysing sequential events in clinical trials.
    Salter A; Raab G; Day S
    Clin Trials; 2006; 3(5):421-30. PubMed ID: 17060216
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of the spending function method and the Christmas tree correction for group sequential trials.
    Stallard N; Facey KM
    J Biopharm Stat; 1996 Jul; 6(3):361-73. PubMed ID: 8854238
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sample size reestimation by Bayesian prediction.
    Wang MD
    Biom J; 2007 Jun; 49(3):365-77. PubMed ID: 17623342
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Constructing multiple test procedures for partially ordered hypothesis sets.
    Edwards D; Madsen J
    Stat Med; 2007 Dec; 26(28):5116-24. PubMed ID: 17476650
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Interim futility analysis with intermediate endpoints.
    Goldman B; LeBlanc M; Crowley J
    Clin Trials; 2008; 5(1):14-22. PubMed ID: 18283075
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Stopping clinical trials early for benefit: impact on estimation.
    Freidlin B; Korn EL
    Clin Trials; 2009 Apr; 6(2):119-25. PubMed ID: 19342463
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Test equality and sample size calculation based on risk difference in a randomized clinical trial with noncompliance and missing outcomes.
    Lui KJ; Chang KC
    Biom J; 2008 Apr; 50(2):224-36. PubMed ID: 18264992
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Interim analysis in therapeutic trials: a brief survey of current developments].
    Falissard B; Lellouch J
    Rev Epidemiol Sante Publique; 1991; 39(4):365-72. PubMed ID: 1754702
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Group sequential clinical trials with triangular continuation regions.
    Whitehead J; Stratton I
    Biometrics; 1983 Mar; 39(1):227-36. PubMed ID: 6871351
    [TBL] [Abstract][Full Text] [Related]  

  • 53. DISPACT trial: a randomized controlled trial to compare two different surgical techniques of DIStal PAnCreaTectomy - study rationale and design.
    Diener MK; Knaebel HP; Witte ST; Rossion I; Kieser M; Buchler MW; Seiler CM;
    Clin Trials; 2008; 5(5):534-45. PubMed ID: 18827046
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Group sequential design for comparative diagnostic accuracy studies.
    Mazumdar M; Liu A
    Stat Med; 2003 Mar; 22(5):727-39. PubMed ID: 12587102
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A comparison of adaptive allocation rules for group-sequential binary response clinical trials.
    Morgan CC; Stephen Coad D
    Stat Med; 2007 Apr; 26(9):1937-54. PubMed ID: 16981177
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Sequential analysis in clinical and epidemiological research].
    van der Tweel I; Schipper M
    Ned Tijdschr Geneeskd; 2002 Dec; 146(49):2348-52. PubMed ID: 12510397
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Design and endpoints of clinical trials in hepatocellular carcinoma.
    Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
    J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Changing frequency of interim analysis in sequential monitoring.
    Lan KK; DeMets DL
    Biometrics; 1989 Sep; 45(3):1017-20. PubMed ID: 2790114
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Information-based monitoring of clinical trials.
    Tsiatis AA
    Stat Med; 2006 Oct; 25(19):3236-44; discussion 3320-5, 3326-47. PubMed ID: 16927248
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Improving the decision to pursue a phase 3 clinical trial by adjusting for patient-specific factors in evaluating phase 2 treatment efficacy data.
    Heller G; Kattan MW; Scher HI
    Med Decis Making; 2007; 27(4):380-6. PubMed ID: 17761958
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.